Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.23876/j.krcp.2018.37.2.148 http://scihub22266oqcxt.onion/10.23876/j.krcp.2018.37.2.148 C6027808!6027808!29971210     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Kidney+Res+Clin+Pract 2018 ; 37 (2): 148-56 Nephropedia Template TP {{tp|p=29971210|t=2018. Obesity may be erythropoietin dose-saving in hemodialysis patients |pdf=|usr=}}{{29971210}} gab.com Text Obesity may be erythropoietin dose-saving in hemodialysis patients JO: Kidney Res Clin Pract http://www.kidney.de/pget.php?&tw=1&pmid=29971210 #FOAvip Background: In dialysis patients, the obesity-survival paradox still requires an explanation. Anemia and high doses of erythropoiesis-stimulating agents (ESAs) are associated with worse outcomes in the hemodialysis (HD) population. In the present study, we explored the relation between obesity and anemia control in a sample of maintenance HD patients in Egypt. Methods: This multicenter observational study included 733 patients on maintenance HD from 9 hemodialysis centers in Egypt. Clinical and laboratory data as well as average doses of ESAs and parenteral iron were recorded. The erythropoietin resistance index (ERI) was calculated. Results: Obesity, defined as a body mass index (BMI) ? 30 kg/m2, was present in 22.6% of the studied population. The target hemoglobin level (10.0?11.5 g/dL) was achieved in 27.3% of non-obese and 25.3% of obese patients, with no significant difference. The median serum ferritin and the values of transferrin saturation index did not differ significantly between these two groups. The weekly ESA dose was significantly lower in obese than in non-obese patients (P = 0.0001). A trend toward higher ESA doses and ERI values was observed in patients with lower BMIs (P < 0.0001). Multiple linear regression revealed that the BMI and urea reduction ratio were the strongest predictors of the ERI. Conclusion: Our study adds more evidence to obesity-associated advantages in HD patients. BMI may determine ESA response, with better responses observed in patients with higher BMIs. Twit Text FOAVip Obesity may be erythropoietin dose-saving in hemodialysis patients ????Kidney Res Clin Pract http://www.kidney.de/pget.php?&tw=1&pmid=29971210 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29971210 #FOAvip English Wikipedia <ref>{{Cite pmid|29971210}}</ref> Obesity may be erythropoietin dose-saving in hemodialysis patients #MMPMID29971210 El-Kannishy GM; Megahed AF; Tawfik MM; El-Said G; Zakaria RT; Mohamed NA; Taha EM; Ammar AA; Abd Eltawab AM; Sayed-Ahmed NA Kidney Res Clin Pract 2018[Jun]; 37 (2): 148-56 PMID29971210show ga Background: In dialysis patients, the obesity-survival paradox still requires an explanation. Anemia and high doses of erythropoiesis-stimulating agents (ESAs) are associated with worse outcomes in the hemodialysis (HD) population. In the present study, we explored the relation between obesity and anemia control in a sample of maintenance HD patients in Egypt. Methods: This multicenter observational study included 733 patients on maintenance HD from 9 hemodialysis centers in Egypt. Clinical and laboratory data as well as average doses of ESAs and parenteral iron were recorded. The erythropoietin resistance index (ERI) was calculated. Results: Obesity, defined as a body mass index (BMI) ? 30 kg/m2, was present in 22.6% of the studied population. The target hemoglobin level (10.0?11.5 g/dL) was achieved in 27.3% of non-obese and 25.3% of obese patients, with no significant difference. The median serum ferritin and the values of transferrin saturation index did not differ significantly between these two groups. The weekly ESA dose was significantly lower in obese than in non-obese patients (P = 0.0001). A trend toward higher ESA doses and ERI values was observed in patients with lower BMIs (P < 0.0001). Multiple linear regression revealed that the BMI and urea reduction ratio were the strongest predictors of the ERI. Conclusion: Our study adds more evidence to obesity-associated advantages in HD patients. BMI may determine ESA response, with better responses observed in patients with higher BMIs. äObesity may be erythropoietin dose-saving in hemodialysis patients (epmc).pdf DeepDyve Pubget Overpricing